Global Gram-Negative Bacterial Infection Market: Alarming Rise in Disease Prevalence to Boost Growth, says TMR Research

San Francisco, California, 19th November 2018: Bacterial infections represent a frequent occurrence in humans. Fortunately, a majority of these infections are successfully eliminated by the native and adaptive immune system. The majority of remaining infections that do require medical assistance can be addressed by physicians outside the hospital setting using a set of generic antibiotics commonly prescribed. A recent market research study, titled as “Gram-Negative Bacterial Infection Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025,” talks about the general market scenario, its drivers, trends, and possible restraints. The report additionally delves into the competitive landscape of the global gram-negative bacterial infection market, elucidating on the strategies to be adopted by vendors in order to gain market traction over the forecast period of 2017 to 2025.

Get Sample Copy of this Report @ 

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94

The absolute most critical driver of development will be the dispatch of a few new novel products amid the figure time frame. These medications won’t just give extra treatment alternatives, particularly for HAIs with carbapenem-safe Enterobacteriaceae (CRE), however will likewise drive by and large market development

The present anti-infection pipeline is commanded by subordinates of normally utilized platforms and blends of beta-lactam anti-microbials with beta-lactamases. In any case, the beginning time pipeline incorporates novel methodologies for new frameworks and elective ways to deal with battle opposition in Gram-negative microorganisms, albeit most are as of now in pre-clinical improvement.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/gram-negative-bacterial-infection-market

Because of the absence of novel frameworks being produced in the course of the most recent couple of decades and restricted ventures into anti-infection R&D as of late, the commonness of safe Gram-negative microorganisms, particularly in the healing center setting, has expanded fundamentally; anti-microbial opposition is presently viewed as a noteworthy risk to the future of current and future trajectories.

Gram-Negative Bacterial Infection Market : Rugged Expansion Foreseen by 2025

Global Gram-Negative Bacterial Infection Market: Snapshot 

Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due to indiscriminate and inappropriate use of antibiotics and a marked decline in the development of efficacious antimicrobial agents. According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.

The burden is more alarming and critical in case of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Patients with MDR Gram-negative bacterial are known to have a higher mortality rate of about 30–70%. Unarguably, they cause higher mortality rates, prolonged hospital stays, and escalated cost of treatment, particularly for patients in intensive care units.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=94

According to the list made public by the WHO, among the various MDR Gram-negative bacterial organisms, few that pose significant reemerging threats and are of high priority include Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae, Enterococcus faecium, Helicobacter pylori, Helicobacter pylori, Neisseria gonorrhoeae. Most of these are associated with causing urinary tract infections, nosocomial infections, and pneumonia. The mounting burden of these infections on public health, especially in emerging nations, is attributed to the rate of antibiotic resistance growing at a faster pace than the pace at which new drugs are being developed Hence, it becomes all the more mandatory that pharmaceutical companies and drug makers to actively focus on expanding the armory of novel therapeutics and accelerate clinical researches in the coming years.

Global Gram-negative Bacterial Infection: Overview

The emergence and proliferation of highly resistant gram-negative bacteria is a major concern given the limited number of antimicrobial agents that are currently available to combat these organisms. The abundant and often inappropriate use of antibiotics is further contributing to the emergence of these organisms. This is creating a pressing need for reliable and effective therapeutics for the treatment of gram-negative bacterial infection. Therefore, the rising research and development activities coupled with increasing investments are driving the global gram-negative bacterial infection market.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=94

The research report offers insights into both existing and therapeutics under development for the treatment of gram-negative bacterial infection. It explores the investments in the pipeline, existing practices, and the latest clinical developments pertaining to the global gram-negative bacterial infection market. It also presents a detailed description of the competitive landscape of the market.

Global Gram-negative Bacterial Infection: Infection-type Segmentation

On the basis of type of infection, the global gram-negative bacterial infection market can be segmented into wound or surgical site infections, pneumonia, urinary tract infections, bloodstream infections, and meningitis. Pneumonia is the most common disease caused gram-negative bacteria followed by urinary tract infections. According to a report by the World Health Organization (WHO), this disease killed 920 136 children under the age of 5 in 2015. Meningitis is also a common disease caused by these organisms. A study conducted by one of the key players in the market, Merck & Co. Inc., indicates that about 25% of the newborns who suffer from gram-negative bacteria induced meningitis die and 15% to 20% of the infants develop serious brain and nerve problems such as enlargement of ventricles, deafness, cerebral palsy, and mental retardation. The alarming rate of mortality and morbidity due to these organisms is escalating the growth of the market.

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/gram-negative-bacterial-infection-market

Global Gram-negative Bacterial Infection: Analysis of Treatment Options

In terms of treatment, the global gram-negative bacterial infection market can be divided into Carbapenems, Colistin, Tigecyclin, Sulbactam, Doxycycline, and Rifampin. The demand for carbapenes is high for the treatment of gram-negative bacterial infections, particularly pneumonia. Some of the most commonly used carbapenes for the treatment of pneumonia are meropenem, imipenem, and doripenem. Sulbactam is majorly used for treatment of meningititis. However, colistin, tigecyclin, doxycycline, and rifampin are used for treating every type of gram-negative bacterial infection and are, therefore, likely to be adopted more in the long run.

Global Gram-negative Bacterial Infection: Competitive Landscape

Players in the global gram-negative bacterial market are primarily focusing on development of more effective drugs. To put this in perspective, Prokarium Ltd. has developed Typhetec for the treatment of gram-negative bacterial infections. Currently, the drug is under phase II clinical trials and on the basis of phase I results, market experts predict that this drug will be beneficial for the treatment of gram-negative bacterial infections in future and will encourage the growth of the market. Some of the key players in the market are Baxter International Inc., Sanofi-Aventis, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc. and Targeted Genetics Corporation.

Gram Negative Bacterial Infection Market Driven by Rising Prevalence of Pneumonia, Meningitis

San Francisco, California, July 19, 2017: TMR Research announces a new report on the global gram-negative bacterial infection market. The report provides readers with a clear picture of the historical development trajectory of the global gram-negative bacterial infection market by profiling the growth of key segments of the market. The competitive dynamics of the gram-negative bacterial infection market are also studied in the report, making it a comprehensive must-have accessory for interested parties in the market. The report is titled ‘Gram-Negative Bacterial Infection Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.’

Gram-negative bacteria constitute a major health threat in several parts of the world due to the severity and diversity of diseases they can cause. The increasing attention being paid to the healthcare sector in several countries is thus likely to be a key driver for the global gram-negative bacterial infection market.

By type of infection, the global gram-negative bacterial infection market is segmented into pneumonia, bloodstream infections, meningitis, urinary tract infections, and surgical site infections. Pneumonia treatment is likely to remain a key revenue channel for the global gram-negative bacterial infection market in the coming years due to the rising prevalence of the disease in emerging regions. The rising air pollution concerns in several countries are also likely to enable a rise in the prevalence of pneumonia, which will aid the gram-negative bacterial infection market’s growth.

Meningitis is also a key health concern across the world. Meningitis caused by gram-negative bacteria has a high fatality count – 25% of newborns suffering from gram-negative bacterial meningitis die, while around 20% suffer from serious nervous and other problems. The key role of gram-negative bacteria in causing meningitis is likely to keep meningitis treatment an important segment of the global gram-negative bacterial infections market.

By treatment type, the global gram-negative bacterial infection market is segmented into carbapenes, rifampin, tigecyclin, colistin, doxycycline, and sulbactam. Carbapenes are likely to dominate the global gram-negative bacterial infection market over the coming years due to their use in the treatment of pneumonia. Sulbactam is also likely to attain a significant role due to the rising prevalence of meningitis across the world. However, rifampin, tigecyclin, colistin, and doxycycline are used in the treatment of multiple gram-negative bacterial infections and are thus likely to retain key shares in the global gram-negative bacterial infections market in the coming years.

The competitive landscape of the global gram-negative bacterial infections market is examined in close detail in the report. Key gram-negative bacterial infection market players profiled in the report include Novartis AG, Baxter International Inc., Pfizer Inc., Dainippon Sumitomo Pharma Co. Ltd., GlaxoSmithKline Plc, Sanofi-Aventis, Nektar Therapeutics, Takeda Pharmaceutical Company Limited, Rib-X Pharmaceuticals Inc., and Targeted Genetics Corporation.